This webcast from January.
Fedratinib was successful trialed as a JAK2 inhibitor and possibly could have been of great benefit to patients who didn’t respond to Ruxo or for whom Ruxo stopped working. However trial was suspended due to health scare re side effects.
Has now been sanctioned for use again and since there is already significant clinical data re efficacy, could be available soon. At the moment I believe Ruxo is the only first line treatment for MF. Hence anyone having a problem (incl falling Platelets) with Ruxo has few options. However there are now several other drugs in the near term pipeline and only time will tell which treatment options are the most superior.
The survival time statistics re MF are now historic and mostly pre date Ruxo, these new drugs should dramatically improve quality of life and buy time for more game changing breakthroughs.
My normal hem retired this week, he send me text saying don’t panic! The difference between now and 10 years ago is amazing and the science improving every year.